{"id":48288,"date":"2022-09-13T09:01:38","date_gmt":"2022-09-13T07:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/"},"modified":"2022-09-13T09:01:38","modified_gmt":"2022-09-13T07:01:38","slug":"one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/","title":{"rendered":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li class=\"bwalignl\">\nThe LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma\n<\/li>\n<li>\nThis study follows One Biosciences\u2019 first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer\n<\/li>\n<li>\nThe initiation of this study follows the completion of a seven million euros financing, initiated at company inception, mid-2020\n<\/li>\n<\/ul>\n<p>PARIS&#8211;(BUSINESS WIRE)&#8211;One Biosciences, a biotech company co-founded by Dr. C\u00e9line Vallot, Institut Curie and Home Biosciences, combining the power of AI and single-cell technologies to discover new therapeutic targets and develop novel precision medicines, announced today that it initiated the LARYCARE prospective clinical study for single-cell profiling of larynx and hypopharynx carcinoma.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/5\/Sans_titre.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg\"><\/a><\/p>\n<p>\nThis new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance. The objective is to identify new predictive biomarkers of the response to neoadjuvant treatment in advanced larynx and hypopharynx carcinoma as well as discover potential new targeted therapies. One Biosciences will evaluate samples from patients enrolled at the Hartmann Clinic and Paris Saint-Joseph Hospital, in partnership with the Research Center of Institut Rafa\u00ebl (Institut Rafa\u00ebl Centre de Recherche).\n<\/p>\n<p>\nThis clinical study follows a first program launched in May 2021 in collaboration with Institut Curie in high grade serous ovarian cancer patients, aiming to identify new precision medicines, evaluating samples from the Institute\u2019s SCANDARE trial.\n<\/p>\n<p>\nOne Biosciences has completed a seven million euros financing initiated at its inception in July 2020 with <b>Home Biosciences<\/b>, an asset centric biotech company, itself backed by US-based <b>Redmile Group<\/b> and France-based <b>Sofinnova Partners<\/b>, two leading VCs in the field of biotech. One Biosciences has also benefited from <b>BPI France\u2019s support through non-dilutive grants <\/b>(BFTE, PIA and Aide au D\u00e9veloppement DeepTech).\n<\/p>\n<p>\n<b>Dr C\u00e9line Vallot<\/b>, <b>co-founder and chair of One Biosciences\u2019 Scientific Advisory Board<\/b>, said: <i>&#8220;Single-cell analysis of tumor tissues during treatment now allows researchers to access an unprecedented level of understanding of cellular mechanisms at work in cancer patients. Using unique molecular technologies and proprietary artificial intelligence algorithms, One Biosciences maps tumors with an unmatched resolution to shed light on new biological markers, making it possible to anticipate the response of each patient to chemotherapy. Our technological platform also paves the way for the development of ultra-targeted therapies against cancers and complex diseases that are difficult to treat.\u201d<\/i>\n<\/p>\n<p>\n<b>Dr.<\/b> <b>Magali Richard<\/b>, <b>co-founder of Home Biosciences and CEO of One Biosciences<\/b>, said<i> &#8220;We have assembled a unique discovery engine in a record timeframe. We are now pursuing our aggressive growth trajectory with two programs already ongoing and two new projects to be soon initiated in high unmet medical needs. We are in line with our initial roadmap and reaffirm our ambition to make One Biosciences a leader in AI and single-cell powered therapeutics development.&#8221;<\/i>\n<\/p>\n<p>\nOne Biosciences is supported by a strong multidisciplinary Scientific Advisory Board, chaired by Dr. C\u00e9line Vallot, One Biosciences\u2019 co-founder, who was awarded, on June 16, 2022, the prestigious CNRS Innovation medal. One Biosciences\u2019 SAB is composed of <b>Alexandre Gramfort, PhD<\/b> Research Director in artificial intelligence at Inria, <b>Sophie Postel-Vinay, MD\/PhD, <\/b>Senior Medical Oncologist &#8211; Clinician Scientist, Drug Development Department (DITEP), Team Leader ATIP U981 INSERM at Gustave Roussy Cancer Campus and <b>Julien Zuber, MD\/PhD, <\/b>Transplant nephrologist at Necker Hospital and Professor of Clinical Immunology at Paris Descartes University.\n<\/p>\n<p>\n<b>About Clinique Hartmann: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ambroisepare.fr%2Fen%2Fclinics%2Fhartmann-clinic&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.ambroisepare.fr%2Fen%2Fclinics%2Fhartmann-clinic&amp;index=1&amp;md5=fcc6edaf253ebfb04a6e5c834334f4ec\" rel=\"nofollow noopener\" shape=\"rect\">www.ambroisepare.fr\/en\/clinics\/hartmann-clinic<\/a>\n<\/p>\n<p>\n<b>About Hopital Paris Saint Joseph:<\/b> <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hpsj.fr&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.hpsj.fr&amp;index=2&amp;md5=2d07e7576eeeca3e6948eb3d25779571\" rel=\"nofollow noopener\" shape=\"rect\">www.hpsj.fr<\/a>\n<\/p>\n<p>\n<b>About Institut Rafa\u00ebl and Institut Rafa\u00ebl Centre de Recherche:<\/b> <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.institut-rafael.fr&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.institut-rafael.fr&amp;index=3&amp;md5=54281ca172c4fa61fd8a041616e41017\" rel=\"nofollow noopener\" shape=\"rect\">www.institut-rafael.fr<\/a>\n<\/p>\n<p>\n<b>About Institut Curie:<\/b> <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.institut-curie.org&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.institut-curie.org&amp;index=4&amp;md5=d0f1fcb77da485f9cc2bcf7d3507b1c8\" rel=\"nofollow noopener\" shape=\"rect\">www.institut-curie.org<\/a>\n<\/p>\n<p>\n<b>and SCANDARE:<\/b> <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftechtransfer.institut-curie.org%2Fpage%2Fclinical-trial-scandare&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftechtransfer.institut-curie.org%2Fpage%2Fclinical-trial-scandare&amp;index=5&amp;md5=e86a66bd8e3d6032cabd1a6f9839d893\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/techtransfer.institut-curie.org\/page\/clinical-trial-scandare<\/a>\n<\/p>\n<p>\n<b>About Home Biosciences: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.homebiosciences.com&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.homebiosciences.com&amp;index=6&amp;md5=d95a00625712bed5f4357142561c53c1\" rel=\"nofollow noopener\" shape=\"rect\">www.homebiosciences.com<\/a>\n<\/p>\n<p>\n<b>About One Biosciences: <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.onebiosciences.fr&amp;esheet=52883566&amp;newsitemid=20220912005815&amp;lan=en-US&amp;anchor=www.onebiosciences.fr&amp;index=7&amp;md5=ad746a6d68a60dea750928d2bb3bf6d8\" rel=\"nofollow noopener\" shape=\"rect\">www.onebiosciences.fr<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>One Biosciences<\/b><br \/>Magali Richard<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#99;&#x6f;&#x6e;t&#97;&#x63;t&#64;&#x6f;&#x6e;e&#98;&#x69;o&#115;&#x63;&#x69;&#101;&#110;&#x63;e&#115;&#x2e;&#x66;&#114;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#111;&#110;t&#x61;&#x63;&#116;&#64;&#x6f;&#x6e;&#101;bi&#x6f;&#115;&#99;i&#x65;&#x6e;&#99;e&#x73;&#x2e;&#102;&#114;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences\u2019 first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48288","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences\u2019 first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T07:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program\",\"datePublished\":\"2022-09-13T07:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/\"},\"wordCount\":637,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005815\\\/en\\\/1568600\\\/21\\\/Sans_titre.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/\",\"name\":\"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005815\\\/en\\\/1568600\\\/21\\\/Sans_titre.jpg\",\"datePublished\":\"2022-09-13T07:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005815\\\/en\\\/1568600\\\/21\\\/Sans_titre.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005815\\\/en\\\/1568600\\\/21\\\/Sans_titre.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/","og_locale":"en_US","og_type":"article","og_title":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend","og_description":"The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences\u2019 first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T07:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program","datePublished":"2022-09-13T07:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/"},"wordCount":637,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/","url":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/","name":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg","datePublished":"2022-09-13T07:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220912005815\/en\/1568600\/21\/Sans_titre.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/one-biosciences-initiates-larycare-clinical-study-its-second-discovery-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48288"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48288\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}